GF
NKTR icon

Goodman Financial’s Nektar Therapeutics NKTR Stock Holding History

Goodman Financial’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-7,083
Closed -$2.13M – 53
2021
Q1 		$2.13M Sell
7,083
-140
-2% -$43.6K 0.68% 33
2020
Q4 		$1.84M Sell
7,223
-724
-9% -$187K 0.64% 32
2020
Q3 		$1.98M Sell
7,947
-149
-2% -$46.9K 0.92% 30
2020
Q2 		$2.81M Sell
8,096
-190
-2% -$59.3K 1.41% 26
2020
Q1 		$2.22M Buy
8,286
+425
+5% +$131K 1.36% 29
2019
Q4 		$2.54M Buy
7,861
+625
+9% +$181K 1.11% 30
2019
Q3 		$1.98M Buy
7,236
+821
+13% +$301K 0.99% 30
2019
Q2 		$3.42M Buy
+6,415
New +$3.22M 1.72% 27

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Goodman Financial's NKTR Position: Q2 2021 in Review

Goodman Financial sold out of Nektar Therapeutics (NKTR) in Q2 2021, closing a stake of 7,083 shares — an estimated $2.13M sold.

Goodman Financial first reported a position in NKTR in Q2 2019 and held it in 8 quarters. The position peaked at $3.42M in Q2 2019. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2021.

  • Goodman Financial reported no remaining Nektar Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Goodman Financial sold 7,083 Nektar Therapeutics shares in Q2 2021, an estimated $2.13M.
  • Goodman Financial first reported a position in Nektar Therapeutics in Q2 2019 and held it in 8 quarters.
  • Goodman Financial's Nektar Therapeutics position peaked at $3.42M in Q2 2019.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2021.

Based on Goodman Financial's 13F filing for Q2 2021, filed 21 Jul 2021.